R10001 |
R788; Fostamatinib |
Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor
|
R10002 |
R406 Free base |
R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free ass
|
R10097 |
GNF-2 |
GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no a
|
R10124 |
PCI32765; Ibrutinib |
Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (
|
R10181 |
AP24534; Ponatinib |
Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VE
|
R10204 |
PF562271 |
PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of
|
R10205 |
PF573228 |
PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-fre
|
R10334 |
SU6656 |
SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 1
|
R10363 |
RN486 |
RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.
|
R10367 |
NVPTAE226 |
TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly p
|
R10496 |
Dasatinib; BMS354825 |
Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src
|
R10503 |
Nilotinib; AMN-107 |
Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine m
|
R10677 |
WH-4-023 |
WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6
|
R10831 |
Dasatinib monohydrate |
Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targe
|
R10873 |
CNX-774 |
CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor wi
|
R10875 |
Entospletinib (GS-9973) |
Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with
|
R10917 |
Radotinib; IY-5511 |
Radotinib is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM,
|
R10967 |
PF-431396 |
PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively
|
R10997 |
GNF-7 |
GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 12
|
R11448 |
R788 |
R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is a Syk
|
R11633 |
GZD824 |
GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(W
|
R11585 |
BAY-61-3606 |
BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM).
|